Drugs / BI 765250
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05728489 | Apr 2023 → Feb 2025 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05151653 | Jan 2022 → Sep 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05728489 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT05151653 ↗ |